Accelerated cross-linking stops keratoconus progression without safety concerns

Accelerated corneal collagen cross-linking may stop the progression of keratoconus, with similar effects as the standard protocol, according to a study.The retrospective chart review evaluated the efficacy of halting progressive keratoconus with accelerated riboflavin ultraviolet A-induced corneal collagen cross-linking at 18 mW/cm² for 5 minutes in 28 eyes.

Ocular Therapeutix™ to Report Third Quarter 2015 Financial Results

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter 2015 financial results on Tuesday, November 10, 2015. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to r